HS Code:
N-(4-Fluorophenyl)-2-hydroxy-N-(1-methylethyl)acetamide (CAS No. 54041-17-7) is a chemical compound classified under HS Code 2924.29.71, which pertains to cyclic amides (including cyclic carbamates) and their derivatives. This compound is primarily used in the pharmaceutical industry as an intermediate or active ingredient in the synthesis of specific drugs or therapeutic agents. Due to its specialized application, trade in this product is often driven by demand from pharmaceutical research and manufacturing sectors, with a focus on markets with advanced healthcare and chemical synthesis capabilities.
Total Trade Volume
Approximately $15 million USD
Data from 2022
Source
Estimated data based on UN Comtrade and industry reports
$5.2 million USD
34.7% of total trade
Increasing
$4.8 million USD
32.0% of total trade
Stable
$2.1 million USD
14.0% of total trade
Increasing
$1.5 million USD
10.0% of total trade
Stable
$0.9 million USD
6.0% of total trade
Decreasing
Average Rate
6.5%
Highest Rate
10% (applied by certain developing countries with protective pharmaceutical policies)
Lowest Rate
0% (under free trade agreements or WTO commitments in major markets like the EU and US)
Rising demand for pharmaceutical intermediates
Increased trade volume due to growth in generic drug manufacturing and R&D activities, particularly in India and China
2021-2022
Shift towards sustainable production
Growing emphasis on green chemistry practices in chemical synthesis, influencing supplier selection and production costs
2022
Supply chain disruptions
Delays and cost increases due to global logistics challenges and raw material shortages post-COVID-19
2020-2022
The European Union introduced stricter import regulations for chemical intermediates, requiring additional safety and environmental compliance certifications.
March 2023
Potential increase in compliance costs for exporters to the EU, possibly affecting trade volumes from non-compliant suppliers.
Indiaโs Production Linked Incentive (PLI) scheme for pharmaceuticals has encouraged domestic production of intermediates like N-(4-Fluorophenyl)-2-hydroxy-N-(1-methylethyl)acetamide.
January 2022
Strengthened Indiaโs position as a leading exporter, potentially increasing global market share.
Ongoing trade tensions have led to fluctuating tariffs on chemical imports between the US and China, impacting supply chains for pharmaceutical intermediates.
Mid-2022
Uncertainty in pricing and sourcing strategies for US-based pharmaceutical companies relying on Chinese suppliers.